Nicolas Pageot

Montpellier, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Journal: Lancet (London, England)

Published: October 25, 2024

Reversible sub-acute motor neuron syndrome after mushroom intoxication masquerading as amyotrophic lateral sclerosis.

Reversible sub-acute motor neuron syndrome after mushroom intoxication masquerading as amyotrophic lateral sclerosis.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: November 26, 2021

Compound heterozygous P67S/D91A SOD1 mutations in an ALS family with apparently sporadic case.

Compound heterozygous P67S/D91A SOD1 mutations in an ALS family with apparently sporadic case.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: October 20, 2021

Increased worsening of amyotrophic lateral sclerosis patients during Covid-19-related lockdown in France.

Increased worsening of amyotrophic lateral sclerosis patients during Covid-19-related lockdown in France.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: February 12, 2021

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2.

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2.

Journal: Brain communications

Published: January 05, 2021

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.

Journal: EBioMedicine

Published: March 31, 2020

Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort.

Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort.

Journal: Frontiers in neuroscience

Published: February 12, 2020

Low 25OH Vitamin D Blood Levels Are Independently Associated With Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study.

Low 25OH Vitamin D Blood Levels Are Independently Associated With Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study.

Journal: Frontiers in neurology

Published: January 07, 2020

Rhythm disturbances as a potential early marker of Parkinson's disease in idiopathic REM sleep behavior disorder.

Rhythm disturbances as a potential early marker of Parkinson's disease in idiopathic REM sleep behavior disorder.

Journal: Annals of clinical and translational neurology

Published: November 22, 2019

High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study.

High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study.

Journal: EClinicalMedicine

Published: June 30, 2019

Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.

Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.

Journal: European journal of neurology

Published: May 23, 2019

Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation.

Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: November 29, 2016

Showing 1-12 of 21

Last Updated: 09/26/2026